Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. sd-rxRNA therapeutics can be used as a standalone treatment or in combination with other modalities.
Provided by Nasdaq.
May 31 - Jun 4, 2019AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
May 31, 2019SACHS ASSOCIATES 5TH ANNUAL IMMUNO-ONCOLOGY BD&L AND INVESTMENT FORUM
Mar 29 - Apr 1, 2019AACR ANNUAL MEETING 2019